Abuse-deterrent formulations (ADF) of opioids resist crushing or dissolving for misuse, helping to curb widespread opioid abuse.

But a recent report from the Institute for Clinical and Economic Review underestimates ADFs’ value by ignoring several key benefits:

**Impact on Reducing Opioid Abuse**
The 14 U.S. reports reviewed by ICER show ADFs providing an average reduction in opioid abuse of 41%. Yet ICER cherry picks a single study for its assessment, citing only a 30% reduction in opioid abuse.

**Ability to Curb Diversion**
ADFs can reduce diversion – where opioids fall into the hands of people without a prescription – by almost 90%.

**Savings on Social Costs**
By reducing abuse and diversion, ADFs can also reduce indirect costs such as lost workplace productivity and criminal justice system expenses.

**Ability to Balance Abuse Reduction and Pain Treatment**
ADFs don’t force patients to choose between treating their pain and preventing potential diversion and misuse of their medications.

*If ICER’s undervalued assessment of ADFs influences health plan coverage, patient access could suffer.*